Qube Research & Technologies LTD Dynavax Technologies Corp Transaction History

Qube Research & Technologies LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$11.7 - $14.98 $396,840 - $508,091	33,918 Added 22.63%	183,785 $2.28 Million
Q4 2023 Feb 13, 2024	BUY	$13.09 - $14.98 $1.96 Million - $2.25 Million	149,867 New	149,867 $2.1 Million
Q1 2023 May 15, 2023	SELL	$9.44 - $11.88 $1.5 Million - $1.89 Million	-158,995 Reduced 67.48%	76,618 $751,000
Q4 2022 Feb 14, 2023	BUY	$10.27 - $13.29 $2.42 Million - $3.13 Million	235,613 New	235,613 $2.51 Million
Q2 2022 Aug 15, 2022	SELL	$7.45 - $12.83 $204,591 - $352,337	-27,462 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$9.75 - $14.44 $267,754 - $396,551	27,462 New	27,462 $298,000
Q4 2020 Feb 16, 2021	SELL	$3.73 - $5.6 $420,964 - $632,010	-112,859 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$4.32 - $11.7 $487,550 - $1.32 Million	112,859 New	112,859 $488,000

274

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.57B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.